Han Biomedical

Han Biomedical Net Debt per Share

The Net Debt per Share of Han Biomedical (6999.TWO) as of Oct 31, 2026 is -9.10 TWD. In the previous year, Net Debt per Share was -7.00 TWD — a change of 29.94% (lower).

Net Debt per Share

-9.10TWD

YoY

29.94%

Last updated:

Net Debt per Share of Han Biomedical is 2024 -9.10 TWD. Net Debt per Share of Han Biomedical was 2023 -7.00 TWD. It decreases by 29.94% lower compared to the previous year.

The Han Biomedical Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2022
-5.57 TWD
Jan 1, 2023
-7.00 TWD
Jan 1, 2024
-9.10 TWD
The Han Biomedical Net Debt per Share history
YEARNet Debt per ShareYoY
-9.10TWD+29.94%
-7.00TWD+25.66%
-5.57TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Han Biomedical Stock analysis

What does Han Biomedical do? Han Biomedical Inc generates revenue through the design, development, and production of medical materials for tissue reconstruction and repair. Its primary products are BarriGel, a post-surgical anti-adhesion solution that prevents complications by extending degradation time, and Hancare, a collagen scaffolding material made from medical-grade collagen that adheres to wounds and absorbs exudate. The company distributes these products mainly within Taiwan's domestic market, targeting healthcare providers and medical facilities that require advanced tissue repair solutions. The firm focuses on natural biomedical materials, emphasizing product innovation for post-surgical care. BarriGel and Hancare are positioned as specialized medical solutions for wound management and adhesion prevention, catering to hospitals and clinics seeking effective tissue repair technologies. Revenue streams are derived from direct sales of these branded products to domestic healthcare institutions without external distribution channels. Han Biomedical Inc's business model centers on proprietary medical materials developed for specific clinical applications. The company's product portfolio includes BarriGel and Hancare, both designed to address post-surgical challenges with natural materials. Domestic market distribution ensures consistent revenue from local healthcare providers who prioritize advanced tissue repair solutions. Han Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Han Biomedical stock

Net Debt per Share of Han Biomedical is -9.10 TWD in 2024.

Net Debt per Share of Han Biomedical changed from -7.00 TWD to -9.10 TWD, representing a 29.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Han Biomedical since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Han Biomedical

All Key Metrics — Han Biomedical